Etga Köprücü

Dr. Etga Köprücü

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
KKKamuran Kalkan
Kamuran Kalkan
VTVEYSEL OZAN TANIK
VEYSEL OZAN TANIK
BKBurak Kardeşler
Burak Kardeşler
EKEtga Köprücü
Etga Köprücü
GÇGülnur Çolak
Gülnur Çolak
BÖBülent Özlek
Bülent Özlek
Background: Malignant ventricular arrhythmias (MVA)—sustained ventricular tachycardia or fibrillation—remain a major early complication after ST-segment elevation myocardial infarction (STEMI) despite timely reperfusion. The no-reflow phenomenon is a key substrate for arrhythmogenesis. The no-reflow prediction in acute coronary syndrome (NORPACS) score, originally developed to predict no-reflow, may also help identify patients at high arrhythmic risk. Methods: We retrospectively analyzed 1050 consecutive STEMI patients undergoing successful primary percutaneous coronary intervention (PCI) between January 2020 and December 2024. The primary endpoint was inhospital MVA. Univariable and multivariable logistic regression models were constructed incorporating clinical, laboratory, and angiographic variables. The incremental predictive value of the NORPACS score was assessed using receiver operating characteristic analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Kaplan–Meier and restricted cubic spline analyses evaluated temporal risk patterns. Results: MVA occurred in 79 patients (7.5%), all within the first 8-h post-PCI. Patients with MVA more often had diabetes, anterior infarcts, lower LVEF, higher inflammatory markers, and no-reflow. The NORPACS score was significantly higher in the MVA group (7.1 ± 1.3 vs. 6.2 ± 1.7, p < 0.001) and independently predicted events across all multivariable models (adjusted OR range: 1.20–1.44, all p < 0.05). Adding NORPACS to clinical–laboratory models improved discrimination (ΔAUC up to 0.07) and yielded significant IDI (0.022–0.024) and NRI (0.10–0.14). Kaplan–Meier curves confirmed earlier arrhythmia onset with higher scores. Conclusions: The NORPACS score is an independent and incremental predictor of early MVA in STEMI patients undergoing PCI. Its integration into clinical–laboratory risk models enhances risk stratification and may guide intensified monitoring in high-risk patients. Prospective multicenter validation is warranted. Graphical This study evaluated the prognostic utility of the NORPACS score for predicting malignant ventricular arrhythmias (VT/VF) in 1050 patients with STEMI undergoing successful primary PCI. The NORPACS score, incorporating angiographic and clinical parameters such as TIMI flow, vessel diameter, stent length, shock status, and ischemia time, was independently associated with inhospital VT/VF risk. Higher NORPACS scores were linked to a stepwise increase in arrhythmic events, as demonstrated by ROC, spline, and Kaplan–Meier analyses. The score remained a significant predictor across all multivariable models (adjusted OR range: 1.20–1.44, all p < 0.05).

13 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KEKemal Eşref Erdoğan
Kemal Eşref Erdoğan
MSMuhammet Fethi Sağlam
Muhammet Fethi Sağlam
SBSerdal Baştuğ
Serdal Baştuğ
BKBurak Kardeşler
Burak Kardeşler
EUEmrah Uguz
Emrah Uguz
MAMurat Akçay
Murat Akçay
Background/Objectives: Real-world data comparing treatment strategies and in-hospital outcomes across no index revascularization, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) in NSTEMI patients remain limited. Methods: In this single-center retrospective cohort study, 1906 NSTEMI patients undergoing coronary angiography were categorized into no index revascularization (n = 946), PCI (n = 709), or CABG (n = 251) groups. The primary endpoint was in-hospital major adverse cardiovascular events (MACE), defined as all-cause mortality, cardiac arrest requiring cardiopulmonary resuscitation, sustained ventricular tachycardia/ventricular fibrillation, dialysis-requiring acute kidney injury, or stroke. Missing data were handled using multiple imputation with chained equations (MICE), and propensity score-based inverse probability of treatment weighting (IPTW) was used as a sensitivity analysis. Results: In-hospital MACE was higher in the no index revascularization group than in the PCI and CABG groups (9.8% vs. 3.5% vs. 4.8%; p < 0.001). Patients managed with no index revascularization were older and had a greater comorbidity burden, lower left ventricular ejection fraction, and more frequent Killip class ≥ 2. In the primary multivariable model, chronic kidney disease, Killip class ≥ 2, lower LVEF, CRP, and male sex were associated with in-hospital MACE, whereas neither PCI nor CABG strategy was independently associated with MACE. IPTW sensitivity analyses yielded similar directions of association; however, the PCI estimate crossed the conventional significance threshold after 1st–99th percentile weight truncation. Conclusions: Patients managed with no index revascularization had a higher baseline risk profile and higher unadjusted in-hospital MACE and mortality. The observed between-group differences should be interpreted as associations rather than causal effects of treatment strategy because of substantial confounding by indication.